<DOC>
	<DOC>NCT01486979</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this trial is to to evaluate the extent of systemic absorption of estradiol during treatment with two different doses of estradiol in postmenopausal women with atrophic vaginitis.</brief_summary>
	<brief_title>Pharmacokinetic Assessment of the Absorption of Estradiol in Postmenopausal Women With Atrophic Vaginitis</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Vaginitis</mesh_term>
	<mesh_term>Atrophic Vaginitis</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Subjects who are able to use German language in speaking and writing Postmenopausal women with at least 5 years after last menstruation, or bilateral oophorectomy performed two years or more prior to the time of screening Serum FSH (Follicle Stimulating Hormone) levels above 40 mIU/ml and estradiol below 20 pg/ml Maximum 5% superficial cells as assessed by evaluation of vaginal cytology Endometrial thickness below 4.0 mm (double layer), as measured by transvaginal ultrasound (if applicable) Availability of a normal mammogram within one year prior to trial start Good general health as assessed by the Investigator and based on medical history, and physical and laboratory examinations Known or suspected allergy to trial product or related products Known, suspected or past history of breast cancer Known, suspected or past estrogen dependent neoplasia e.g. endometrial cancer Endometrial hyperplasia or endometrial polyps diagnosed during the screening period Abnormal genital bleeding of unknown etiology Previous estrogen and/ or progestin hormone replacement therapy</criteria>
	<gender>Female</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>